Exagen Inc. (XGN:NASDAQ) closed at $7.27 on October 23, 2026, down 2.81% on the day. The stock trades 40.6% below its 52-week high of $12.23 and 180.7% above its 52-week low of $2.59. Over the past year, it lost 39.2%. Exagen Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, XGN closed higher on 113 days (45%). Its best day was August 4, 2026 (+37.82%) and its worst was January 13, 2026 (-13.45%). The stock moved 10% or more in a single session 9 times. It opened at least 5% above the previous day's high 2 times.
Exagen Diagnostics Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.
Find more stocks like XGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.